PTU - Polskie Towarzystwo Urologiczne
list of articles:

Article published in Urologia Polska 1999/52/4.


Ewa Sommer, Krzysztof Pastewka, Ewa Skopińska-Różewska, Małgorzata Filewska, Beata Białas-Chromiec, Mirosław Kazoń
Zakład Immunologii Instytutu GruĽlicy i Chorób Płuc w Warszawie
Kierownik: prof. dr hab. E. Skopińska-Różewska
Klinika Urologii CMKP w Warszawie
Kierownik: prof. dr hab. A. Borówka
Zakład Patomorfologii CMKP w Warszawie
Kierownik: dr med. K. Bardadin


neoplasma non?steroidal antiinflammatory drugs ? Piroxicam ? angiogenesis ? antiangiogenic activity


Objective. Evidence of cancer chemopreventive potential of non-steroidal
antiinflammatory drugs (NSAIDs) has recently been accumulated from
experimental in vivo carcinogenesis and epidemiological studies. Although
inhibition by NSAIDs of cyclooxygenase activity has been postulated to be
involved in their cancer chemopreventive effects, the mechanism is not clear.
Because tumour formation is strictly dependent upon neovascularisation we
explored the possibility that inhibition of angiogenesis may contribute to
antineoplastic properties of piroxicam.
Material and methods. Tumour cells were isolated from 6 human kidney
and 4 urinary bladder tumours removed during operation. We used the mouse
cutaneous angiogenic test of Sidky and Auerbach, in our modification. The
full suspension of tumour cells were grafted id. into Balb/c mice. Mice were
then fed for 3 days with 0.02-0.4 mg/mouse piroxicam. Three days after cells
grafting mice were sacrificed and newly-formed blood yessels were counted
in dissection microscope.
Results. Piroxicam significantly inhibited the angiogenic activity at doses
0.02-0.4 mg/mice.
Conclusion. Piroxicam posses antiangiogenic activity.


  1. [1] Barenbaum, A., LeDenmat, R, Nevalainem, T., Masliah,J., Fournier, C:
  2. Interleukin-l-induced prostaglandyn E biosynthcsis in human synouialc cells invo-
  3. lves the actwation of' cytosoiic phospholipase A and cyclooxygenase-2. Eur. J. Bio-
  4. chem. 1994, 226, 125-131.
  5. [2] DuBois, M., Giardello, F., Smalley, W.: Nonsteroidal anti-inflammatory drugs,
  6. eicosanoids, and colorectal cancerprcvention. Gastroenterol. Clin. North. Am. 1996,
  7. 25, 773-791.
  8. [3] Hanif, R., Pittas, A., Feng, Y., Koutsos, M., Qiao, L., Staiano Coico, L.,
  9. Shiff, S. I., Rigas, B.: Effect of nonsteroidal anti-inflammatory drugs on prolifera-
  10. tion and on induction of apoptosis in colon cancer cells by a Prostaglandin-indepen-
  11. dent pathway. Biochem. Pharmacol. 1996, 52, 237-245.
  12. [4] Hubbard, W., Alley, M., McLemore, T., Boyd, M.: Profiles of Prostaglandin
  13. biosynthesis in sixteen established cell lines derived from human lung, colon, prostate
  14. and ovarian tumors. Canc. Res. 1998, 48, 4770-4775.
  15. [5] Kargmann, S., O'Neill, G., Vickers, P, Evans, J., Mancini, J., Jothy, S.:
  16. Expression of Prostaglandin G/H synthasel and 2 protein in human colon cancer.
  17. Cancer Res. 1995, 55, 2256-2259.
  18. [6] Moon, R., Kelloff, G., Detrisac, C, Steele, V., Thomas, C: Chemoprevention
  19. of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis 1993,14,
  20. 1487-1489.
  21. [7] Noguchi, M., Eavashi, M., Minami, M., Kinoshita, K., Miyazaki, I.: Ef-
  22. fects of eicosapentaenoic acid on cell growth and Prostaglandin E and leukotriene B.
  23. production by a human breast cancer cell line (MDA-MB-231). Oncology 1995,52,
  24. 458-264.
  25. [8] Okajima, E., Ozono, S., Endo, T., Majima, T., Tsutsumi, M., Fukuda, T.,
  26. Akai, H., Denda A., Hirao, Y., Okajima, E., Nishino, H., Nir, Z.,
  27. Kon ishi, Y.: Chemopreven tive efficacy of piroxicam administered alone or in Combi-
  28. nation with lycopene and ?-carotene on the development of rat urinary bladder car-
  29. cinoma after N-butyl-N(4-hydroxybutyl) nitrosamine treatment. Japan. J. Cancer
  30. Res. 1997, 88, 543-552.
  31. [9] Quesada, C, Kimata, H., Mori, M., Nishimura, M., Tsuneyoshi, T.,
  32. Baba, S.: Piroxicam and acarbose are chemopreventive agents for spontaneous inter-
  33. stinal adenomas in APC gene 1309 knockout mice. Japan. J. Cancer Res. 1998,89,
  34. 392-396.
  35. [10] Rao, K., Detrisac, C, Steele, V., Hawk, E., Kelloff, G., Mc Comic, D.:
  36. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive
  37. agents in the mouse urinary bladder. Carcinogenesis 1996,17,1435-1438.
  38. [11] Reddy, B., Maruyama, H., Kelloff, G.: Dose-related inhibition of colon carcino-
  39. genesis by dietary piroxicam, a nonsteroidal antiinflammatory drug during different
  40. stages of rat colon tumor development. Canc. Res. 1987,47, 5340-5346.
  41. [12] Shibata, M., Hasegawa, R., Shivai, T., Takesada, Y., Fukushima, S.: Che-
  42. moprevention by indomethacin of tumor promotion in a rat urinary bladder carcino-
  43. genesis model. Inter. J. Cancer 1993, 55,1011-1017.
  44. [13] Shiff, S., Koutsos, M.I., Qiao, L., Rigas, B.: Nonsteroidal antiinflammatory
  45. drugs inhibit the proliferation of colon adenocarcinoma cells: effect on cell cycle and
  46. apoptosis. Exp. Cell. Res. 1996, 222,179-188.
  47. [14] Sidky, V. A., Auerbach, R.: Lymphocyte-induced angiogenesis: A quantitative
  48. and sensitive assay by modified assay of the graft-vs-host reaction. J. Exp. Med.
  49. 1975, 141, 1084.
  50. [15] Skopińska-Różewska, E., Sommer, E., Demkow, U., Chorostowska-Wy-
  51. nimko, J., Bałan B., Różycka, B., Barcz, E., Filewska, M., Mlekodaj, ¦.,
  52. Rudziński, R, Seweryniak, W., Caban, R, Kupis, W., Bogdan, ]., Usiek-
  53. niewicz, R, G±tarek, ]., Langfort, R.: Screening of angiogenesis inhibitors by
  54. modified tumor-induced angiogenesis (TIA) test in lung cancer. Ann. Acad. Med.
  55. Bialostocensis 1997, 42, (Suppl. 1), 287-296.
  56. [16] Skopińska-Różewska, E., Piazza, G. A., Sommer, E., Pamukcu, R., Barcz,
  57. E., Filewska, M., Kupis, W., Caban, R, Rudziński, R, Bogdan, ]., Mleko-
  58. daj, S. Sikorska, E.: Inhibition of angiogenesis by sulindac and its sulfone metabo-
  59. lite (FGN-1): A potential mechanism for their antineoplastic properties. Inter. J. Tiss.
  60. React. 1998, 20, 85-89.
  61. [17] Sommer, E.: Antynowotworowe dzałanie niesteroidowych leków przeciwzapalnych
  62. ze szczególnym uwzględnieniem Sulindaku. Terapia 1998, 7, 31-33.
  63. [18] Tanaka, T. Nishikawa, A., Mori, Y., Morishita, Y., Mori, H.: Inhibitory
  64. effects of nonsteroidal antiinflammatory drugs, Piroxicam and Indomethacin on 4-
  65. Nitroquinoline l-oxide-induced ton±ue carcinogenesis in male ACI/N rats. Canc.
  66. Lett. 1989, 48,177-182.
  67. [19] Thompson, H.; Briggs, S., Paranka, R, Piazza, G., Brendel, K., Gross, R,
  68. Sperl, G., Pamukcu, R., Ahnen, S.: Inhibition of mammary carcinogenesis in
  69. rats by sulfone metabolite of Sulindac. J. Natl. Cancer Inst. 1995,16,1259-1260.
  70. [20] Thun, M., Namboodini, M., Heath, C: Aspirin use and reduced risk offatal
  71. colon cancer. N. Engl. J. Med. 1991,325,1593-1596.